HK Stock MarketDetailed Quotes

06600 SCICLONE PHARMA

Watchlist
  • 18.000
  • +0.020+0.11%
Trading Apr 26 13:28 CST
11.30BMarket Cap9.13P/E (TTM)

About SCICLONE PHARMA Company

Saisheng's vision We focus on the treatment of oncology and severe infectious diseases. We are committed to winning patients' trust, customer respect, employee pride, and continuing to grow to become an international biopharmaceutical company focusing on the Chinese market Saisheng's mission Taking patient health as our mission to provide international quality medical products and services Saisheng's values clients Customers come first, and all of our work is centered around meeting their legitimate needs. Win-win Taking a win-win situation as the starting point, we treat our internal and external work partners honestly, trust and benefit each other in everything we do. Responsible Carry forward the spirit of ownership, dare to make decisions, and take responsibility. On the basis of completing my job with quality and quantity, I take the initiative to take on additional important work and take responsibility until the end. efficient The division of labor is clear, processes are simplified; quick response and effective execution; innovative methods are used to solve problems, taking into account efficiency and efficiency. performance Guided by results, exceeding the average level of development of the industry as the starting point for our performance standards, using high performance as the realization of self-worth, we continuously climb higher and more challenging performance goals and surpass ourselves. compliance Compliance is the cornerstone of our business. We always stick to the bottom line, follow the rules, obey discipline, and do the right thing. Saisheng Strategy At Saison, our vision is to focus on the treatment of major and specific diseases, and is committed to winning patients' trust, customer respect, employee pride, and continuing to grow to become a first-class healthcare enterprise focusing on the Chinese market. Saison has been deeply involved in the Chinese market for over 20 years, and our mission and vision have always guided our daily business. We will use our product development and commercialization capabilities to achieve our goals and mission by implementing the following key strategies: Continue to strengthen the marketing product portfolio through effective lifecycle management Optimize our pipeline by accelerating rapid listing strategies for late-stage assets and focusing on potential start-ups or best-in-class early-stage assets Continue to innovate business models and enhance commercialization and development capabilities Committed to developing talent and enhancing our operating infrastructure to support our future expansion.

Company Profile

Symbol06600
Company NameSCICLONE PHARMA
ISINKYG4271B1023
Listing DateMar 3, 2021
Issue Price18.80
Shares Offered115.98M share(s)
FoundedMay 13, 2020
Registered AddressCayman Islands
ChairmanLI Zhenfu
Secretaryrongrong pan
Audit InstitutionPricewaterhouseCoopers
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficePO Box 309, Ugland House Grand Cayman, KY1-1104 Cayman Islands
Head Office and Principal Place of BusinessRoom 3401A, Royal House, 311 Gloucester Road, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
Employees1050
MarketHong Kong motherboard
Emailir@sciclone.com
Business Saisheng Pharmaceutical Holdings Co., Ltd. is a Chinese biopharmaceutical company mainly engaged in the development and sale of listed product portfolios and research products in key treatment areas (including tumors and severe infections). The company mainly sells its own products, sells imported products and sells promotional products on behalf of business partners in China.

Company Executives

  • Name
  • Position
  • Salary
  • hong zhao
  • CEOs,President,Executive Director,Remuneration Committee Members,Authorized Representative
  • --
  • rongrong pan
  • Executive Director,Company Secretary,Authorized Representative
  • --
  • LI Zhenfu
  • Chairman,Non-executive directors,Chairman of the Nomination Committee
  • --
  • VASELLA Daniel Luzius
  • Non-executive directors
  • --
  • LIN Shirley Yi-Hsien
  • Non-executive directors,Audit Committee Members
  • --
  • haixia wang
  • Non-executive directors
  • --
  • guoen liu
  • Independent Non-Executive Director,Nomination Committee Members
  • --
  • CHEN Ping
  • Independent Non-Executive Director,Remuneration Committee Members
  • --
  • GU Alex Yushao
  • Independent Non-Executive Director,Remuneration Committee Chairman,Audit Committee Members
  • --
  • HAYES Wendy
  • Independent Non-Executive Director,Chairman of the Audit Committee,Nomination Committee Members
  • --
  • li mao
  • VP,Chief Medical Officer,General Manager of Research and Development
  • --
  • zhiwen shao
  • VP
  • --
  • mingxiang wu
  • VP
  • --
  • yansong chang
  • VP,Vice President and General Manager of the Oncology Division
  • --
  • lingyu zhu
  • VP,Chief Business Development Officer
  • --
  • min jia
  • VP,General Manager of Immunization Division
  • --
  • lianzong wu
  • VP
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg